gallocatechol has been researched along with Alzheimer Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cima-Omori, MS; Dominguez-Meijide, A; Griesinger, C; Ibáñez de Opakua, A; König, A; Leonov, A; Outeiro, TF; Ryazanov, S; Vasili, E; Zweckstetter, M | 1 |
| Choudhry, F; Cox, CJ; Francis, PT; Howlett, DR; Lichtenthaler, SF; Peacey, E; Perkinton, MS; Richardson, JC; Williams, RJ | 1 |
2 other study(ies) available for gallocatechol and Alzheimer Disease
| Article | Year |
|---|---|
Effects of pharmacological modulators of α-synuclein and tau aggregation and internalization.
Topics: alpha-Synuclein; Alzheimer Disease; Benzodioxoles; Benzopyrans; Brain; Catechin; Cells, Cultured; Humans; Hydrazones; Lewy Bodies; Molecular Targeted Therapy; Neurofibrillary Tangles; Parkinson Disease; Protein Aggregates; Protein Aggregation, Pathological; Pyrazoles; tau Proteins | 2020 |
Dietary (-)-epicatechin as a potent inhibitor of βγ-secretase amyloid precursor protein processing.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Catechin; Cells, Cultured; Disease Progression; Male; Mice, Transgenic | 2015 |